Table of Contents
1. Overview and Scope
1.1. Research goal & scope
1.2. Research assumptions
1.3. Research Methodology
1.3.1. Primary data sources
1.3.2. Secondary data sources
1.4. Key take-aways
1.5. Stakeholders
2. Executive Summary
2.1. Market Definition
2.2. Market Segmentation
3. Hematologic Malignancies Therapeutics Market Insights
3.1. Hematologic Malignancies Therapeutics– Industry snapshot
3.2. Hematologic Malignancies Therapeutics- Ecosystem analysis
3.3. Hematologic Malignancies Therapeutics Market dynamics
3.3.1. Hematologic Malignancies Therapeutics– Market Forces
3.3.1.1. Hematologic Malignancies Therapeutics Market driver analysis
3.3.1.2. Hematologic Malignancies Therapeutics Market restraint/challenges analysis
3.3.1.3. Hematologic Malignancies Therapeutics Market opportunity analysis
3.4. Industry analysis - Porter's five force
3.4.1. Bargaining power of supplier
3.4.2. Bargaining power of buyer
3.4.3. Threat of substitute
3.4.4. Threat of new entrant
3.4.5. Degree of competition
3.5. Hematologic Malignancies Therapeutics Market PEST analysis, 2017
3.6. Hematologic Malignancies Therapeutics Industry trends
3.7. Competitive Ranking Analysis
4. Hematologic Malignancies Therapeutics Market Size and Forecast by Type
4.1. Key findings
4.2. Leukemia
4.2.1. Global market estimates and forecasts, 2017 – 2025
4.2.1.1. Acute Lymphocytic Leukemia
4.2.1.2. Chronic Lymphocytic Leukemia
4.2.1.3. Acute Myeloid Leukemia
4.2.1.4. Chronic Myeloid Leukemia
4.2.2. Lymphoma
4.2.2.1. Global market estimates and forecasts, 2017 – 2025
4.2.3. Multiple Myeloma
4.2.3.1. Global market estimates and forecasts, 2017 – 2025
4.2.4. Others
4.2.4.1. Global market estimates and forecasts, 2017 – 2025
5. Hematologic Malignancies Therapeutics Market Size and Forecast by Therapy
5.1. Key findings
5.2. Chemotherapy
5.2.1. Global market estimates and forecasts, 2017 – 2025
5.3. Radiotherapy
5.3.1. Global market estimates and forecasts, 2017 – 2025
5.4. Immunotherapy
5.4.1. Global market estimates and forecasts, 2017 – 2025
5.5. Stem Cell Transplantation
5.5.1. Global market estimates and forecasts, 2017 – 2025
5.6. Others
5.6.1. Global market estimates and forecasts, 2017 – 2025
6. Hematologic Malignancies Therapeutics Market Size and Forecast by Regions
6.1. Key findings
6.2. North America
6.2.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.2.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.2.3. U.S.
6.2.3.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.2.3.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.2.4. Canada
6.2.5. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.2.6. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.3. Europe
6.3.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.3.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.3.3. Germany
6.3.3.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.3.3.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.3.4. UK
6.3.4.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.3.4.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.3.5. France
6.3.5.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.3.5.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.3.6. Italy
6.3.6.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.3.6.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.4. Asia Pacific
6.4.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.4.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.4.3. China
6.4.3.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.4.3.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.4.4. India
6.4.4.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.4.4.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.4.5. Japan
6.4.5.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.4.5.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.5. Latin America
6.5.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.5.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.5.3. Brazil
6.5.3.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.5.3.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.5.4. Mexico
6.5.4.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.5.4.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.6. Middle East & Africa
6.6.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.6.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
7. Company Profiles
7.1. Pfizer, Inc.
7.1.1. Overview
7.1.2. Financials
7.1.3. Product Benchmarking
7.1.4. Recent Developments
7.2. Hoffmann-LA Roche ltd
7.2.1. Overview
7.2.2. Financials
7.2.3. Product Benchmarking
7.2.4. Recent Developments
7.3. Sanofi-Aventis
7.3.1. Overview
7.3.2. Financials
7.3.3. Product Benchmarking
7.3.4. Recent Developments
7.4. Bristol-Myers Squibb Company
7.4.1. Overview
7.4.2. Financials
7.4.3. Product Benchmarking
7.4.4. Recent Developments
7.5. AbbVie, Inc.
7.5.1. Overview
7.5.2. Financials
7.5.3. Product Benchmarking
7.5.4. Recent Developments
7.6. Novartis AG
7.6.1. Overview
7.6.2. Financials
7.6.3. Product Benchmarking
7.6.4. Recent Developments
7.7. GlaxoSmithKline PLC
7.7.1. Overview
7.7.2. Financials
7.7.3. Product Benchmarking
7.7.4. Recent Developments
7.8. Celgene Corporation
7.8.1. Overview
7.8.2. Financials
7.8.3. Product Benchmarking
7.8.4. Recent Developments
7.9. Johnson & Johnson Services, Inc.
7.9.1. Overview
7.9.2. Financials
7.9.3. Product Benchmarking
7.9.4. Recent Developments
7.10. Takeda Pharmaceutical Company limited
7.10.1. Overview
7.10.2. Financials
7.10.3. Product Benchmarking
7.10.4. Recent Developments